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Binding properties of mono- and dimeric pyridine 
dicarboxamide ligands to human telomeric higher-
order  G-quadruplex structures† 
C. Saintome´,‡ab P. Alberti,‡a N. Guinot,a P. Lejault,a J. Chatain,a P. Mailliet,a J.-
F.  Riou  a and   A. Bugauta 
 
Here, we report on the in vitro binding properties of the known 
pyridine dicarboxamide G-quadruplex ligand 360A and a new 
dimeric analogue (360A)2A to human telomeric DNA higher-order 
G-quadruplex (G4) structures. This study points to original binding 
features never reported for G4 ligands, and reveals a greater 
eﬃciency for the dimeric ligand to displace RPA (a ssDNA binding 
protein involved in telomere replication) from telomeric    DNA. 
 
In normal human somatic cells, telomeric DNA typically spans a 
4–15 kb double-stranded region composed of 50-TTAGGG-30/ 30-
AATCCC-50 tandem repeats that ends with an about 150–300 nt 
single-stranded  30-overhang.1   The  G-rich  strand  of  telomeric 
DNA is prone to fold into G4 structures, which have been 
visualised in human cells using a structure-specific antibody.2 
Over the past two decades, a large number of small molecules 
have been synthesized and tested for their potential to interact 
with human telomeric G4 structures.3 Some of these G4 ligands 
have been reported as telomere-targeting agents able to interfere 
with the  binding of telomere-associated   proteins.4 
So far, most of the studies on the  interactions  between 
human telomeric DNA and G4 ligands have focused on short 
sequences able to fold into a single G4 unit. However, others  
and we have shown that longer telomeric DNA sequences can 
form higher-order structures consisting of  several  contiguous  
G4  units  joined  by  TTA  linkers.5,6  A  few  recent  studies have 
indicated that the binding properties of a ligand to multimeric 
G4 structures can significantly diﬀer from its binding to a 
single G4 unit.7 
Pyridine dicarboxamide derivatives are synthetic organic 
molecules that are amongst the most potent and selective G4 
ligands.  A  lead  molecule  from  this  family  is  360A  (Fig. 1A), 
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which we previously developed and was the first molecule of 
this family to be evaluated for its G4 binding properties.8 This 
molecule was shown to display a good selectivity for G4 
structures as compared with double-stranded DNA, and it was 
demonstrated that 360A preferentially localises at telomeres in 
human living cells.9 The use of dimeric G4 ligands,  composed 
 
 
Fig. 1 (A) Chemical structures of the G4 ligands used in this study. 
Counter ions are I-. (B and D) Changes in the CD spectrum and (C and E) 
changes in the maximum CD value of H21 (6 mM in 10 mM lithium 
cacodylate pH 7.2, 100 mM NaCl) upon addition of increasing amounts of 
360A and (360A)2A. 
 
 
   
  
 
of two G4 ligand moieties linked together by a chemical arm, 
has been proposed as a possible means to enforce the targeting 
of contiguous telomeric G4s.10 In this work, we have synthe- 
sized a dimer of 360A (see Materials and methods in ESI†), 
named (360A)2A (Fig. 1A); and we have characterized the bind- 
ing of 360A and its newly synthesized dimeric form (360A)2A 
to human telomere-mimicking oligonucleotides forming an 
increasing number of contiguous G4  units. 
In order to assess the stabilization and selectivity of (360A)2A 
towards human telomeric G4s, we performed competitive FRET-
melting experiments in the  presence  of  a  large  excess  of 
unlabelled double-stranded DNA (ds26, Table S1, ESI†). We 
used either a fluorescent-labelled 21 nt oligonucleotide (F21T), 
which forms a single telomeric G4 structure, or three oligo- 
nucleotides (H69Q1, H69Q2 and H69Q3) that form fluorescent- 
labelled contiguous G4s (see Materials and methods in ESI†). 
The results demonstrated that the dimer ligand is a strong 
stabilizer of telomeric G4s and exhibits a great G4 vs. duplex 
selectivity (Fig. S1, ESI†). 
Next, we used CD spectroscopy to evaluate the binding 
stoichiometry.11 We first carried out CD titration experiments 
using H21 oligonucleotide that folds into a single G4 unit 
(Table S1, ESI†). We titrated a 6 mM solution of H21 in a sodium 
containing buﬀer with increasing amounts of 360A or its dimer 
analogue (360A)2A. The changes in the CD spectrum of H21 
upon increasing the concentration of 360A ligand up to 30 mM 
by increments of 1 mM are shown in Fig. 1B. In the absence of 
ligand, the CD spectrum of H21 displayed the characteristic 
signature of an antiparallel G-quadruplex structure, with a 
major positive band around 295 nm and a negative band at 
about 265 nm. Addition of 360A led  to an  increase in  the  
295 nm band up to about a 12 mM ligand concentration in 
solution, at which a maximum amplitude was reached. The  
spectral changes occurred immediately after each addition, and 
did not progress over time. This result indicated a 2 : 1 molar 
ratio of 360A to H21, presumably involving interactions with 
the two terminal G-quartets of the G4 structure. Stoichiometry 
values and associated errors were also determined by multiple 
linear regression analyses (Fig. 1C and Table S2, ESI†), with 
systematically varying the range of fitting. Titration of a 6 mM 
solution of H21 with (360A)2A showed again an increase of the 
positive band around 295 nm (Fig. 1D); however, a maximum 
value was reached at around 7 mM ligand concentration, 
indicating a 1 : 1 binding stoichiometry of (360A)2A to H21 
(Fig. 1E).§ This suggests that the chemical arm between the 
two aromatic G4-binding moieties is long enough to aﬀord  
them interacting with the top and the bottom G-quartet sur- 
faces of the G4 structure in a ‘‘sandwich-like’’ manner. Such 
result is comparable to other studies from the Nagasawa’s 
laboratory on dimers of macrocyclic hexaoxazole ligands.12 
We then investigated the binding stoichiometry of 360A and 
(360A)2A to telomeric oligonucleotides able to form two and 
three contiguous intramolecular G4 structures, named  H45 
and H69, respectively (Table S1, ESI†).6 In these experiments, 
DNA strand concentrations were adjusted in order to maintain 
an   identical   G4   unit   concentration   (6   mM)   in solution. 
 
 
Fig. 2 (A and C) Changes in the CD spectrum and (B and D) changes in 
the maximum CD value of H69 (2 mM in 10 mM lithium cacodylate pH 7.2, 
100 mM NaCl) upon addition of increasing amounts of 360A and (360A)2A. 
 
 
 
Consequently, in the absence of ligand, the CD spectra of   
H45 and H69 have similar shapes and amplitudes (Fig. 2 and 
Fig. S3, ESI†).6 As for H21, we also observed an increase in the 
positive CD signal around 295 nm upon increasing the concen- 
tration of ligand in solution, until it reached a maximum value 
(Fig. 2 and Fig. S3, ESI†). However, from these experiments, we 
determined ligand to G4 unit molar ratios higher than the one 
obtained for H21 (see Table S2, ESI†). For 360A, the determined 
binding stoichiometry was around 2.5 with H45 (Fig. S3A and B, 
ESI†), and 2.7 with H69 (Fig. 2A and B); while for (360A)2A,  
it was around 1.5 and 1.7 for  H45  and  H69,  respectively 
(Fig. 2C, D and Fig. S3C, D, ESI†). 
These binding stoichiometries that  exceeded  what  could 
be conceived by taking into account the results obtained with 
H21 suggested that new binding sites became available when 
telomeric G4 units are arranged contiguously. Noteworthily, 
the obtained binding stoichiometries seemed to increase with 
the length of the oligonucleotide used, matching with the 
number of TTA linkers anchoring the G4 units together. If a 
TTA linker gives rise to one extra binding site for the ligands, the 
calculated 360A : G4 unit molar ratios would be of 2.50 for H45 
and of 2.67 for H69 (Table S2, ESI†). These calculated values are 
very close to our experimental values (Fig. 3 and Table S2, ESI†). 
This has also been verified for H93, an oligonucleotide capable of 
forming four contiguous G4 units (Fig. 3 and Tables S1, S2, ESI†). 
For the dimeric ligand (360A)2A, the experimental ligand : G4 ratio 
values also followed the trend of the calculated values (Fig. 3 and 
Table S2, ESI†). These results indicate that, for both 360A and 
(360A)2A, a binding site exists between two adjacent G4 units in a 
multimeric telomeric G4  structure. 
To further investigate this possibility, we next wondered 
whether the observed stoichiometry values depended on the 
   
  
 
 
 
Fig. 3 Calculated (open circle) versus experimental (open square) ligand 
to G4 ratio values (Table S2, ESI†) for the telomeric oligonucleotides H21, 
H45, H69 and H93 (see Fig. S4 in ESI†) and the extended oligonucleotides 
H45(TTA)3 and H69(TTA)3. Data for 360A and (360A)2A are in blue and red, 
respectively. 
 
 
length of the TTA nucleotidic linker that joins the G4 units. We 
performed CD titrations with oligonucleotides bearing longer 
TTA linkers between the G4 units (H45(TTA)3 and H69(TTA)3, 
Table S1, ESI†). From these experiments, we determined a  
binding stoichiometry of 2 : 1 for 360A and 1 : 1 for its dimeric 
analogue (360A)2A for both H45(TTA)3 and H69(TTA)3 oligo- 
nucleotides (Fig. 3 and Fig. S5, ESI†). These values are similar 
to the ones obtained for the single G4-forming sequence H21, 
indicating that the extra interstitial binding sites within the 
multimeric G4 structures are lost when the G4 units are moved 
away by additional TTA sequences. 
Overall, our results point to  a  binding  model  whereby  
two aromatic G4-binding moieties interact with the external 
G-quartets of a G4 unit and a third one is accommodated in a 
binding pocket involving the TTA linker between two contiguous 
G4s. On the basis of molecular modelling simulations, Haider 
et al. proposed the existence of possible binding    sites at the 
interface between two adjacent telomeric G4    units.13  Subse- 
quently, few G4 ligands have been studied experimentally for 
their binding to multimeric G4 structures.7 Among  them,  a 
chiral cyclic helicene has been proposed to bind in the cleft 
pocket located between two adjacent human telomeric G4s.7b 
Cummaro et al. reported a spectroscopic study on the binding of 
a triazatruxene molecule to a telomeric higher-order structure 
formed by two G4 units, which revealed that two molecules could 
bind by end-stacking at the 50 and 30 extremities of the structure 
and a third molecule at the interface between the G4s.7c Bai et al. 
also proposed a similar binding mode for sanguinarine to a two- 
tandem G4-forming sequence.7a Recently, a triaryl-substituted 
imidazole derivative was also found to selectively bind to 
telomeric G4 multimers likely through intercalating into the 
pocket formed between two G4 units.7j By contrast no intersitial 
binding sites between adjacent G4s were observed for a macro- 
cyclic hexaoxazole ligand.7f Regarding the binding of ligand 
dimers to higher-order G4 structures, there has been only very 
few studies.10 All these studies were carried on telomeric 
sequences forming two contiguous G4 structures, and no inter- 
stitial binding site was observed. Thus, when compared to 
previous works, our results indicate unprecedented modes of 
binding to multimeric G4 structures for 360A and its dimeric 
analogue   (360A)2A,   which   combine   end-stacking   with   both 
external G-quartets of the G4 units and additional binding sites 
between the G4s. Detailed information on how these extra 
binding sites occur, and whether they pre-exist or are generated 
upon binding of the ligands to the G-quartets will require in-
depth structural studies. 
We next sought to assess the potential of our G4 ligands to 
interfere with the binding of human replication protein A (RPA) 
to telomeric DNA. RPA is a single-stranded DNA (ssDNA) 
binding protein that is essential to whole genome replication, 
including telomeres.14 We previously showed that the eﬃciency 
of RPA binding to G4-forming telomeric sequences displays an 
inverse relationship with the stability of the formed  structure, 
and that G4 ligands can impair RPA binding to single telomeric 
G4-forming sequences.15 We carried out gel shift  experiments 
with RPA and the telomere-mimicking oligonucleotides used in 
this study. For these experiments, RPA concentration in the 
reaction mixture was set to obtain about 95–100%  DNA  bound 
to RPA for all the sequences used. First, we incubated the G4 
ligand and the radiolabelled DNA substrate for 5 min, and then 
we added RPA to the reaction mixture and incubated for    further 
20 min. We observed a concentration-dependent inhibitory 
effect of the ligands for the association between RPA and the 
DNA substrates (Fig. 4A and Fig. S6A, ESI†). The ability of 
the ligands to inhibit RPA binding was maintained even in the 
presence of a large excess of the double-stranded competitor 
ds26 (Fig. S7, ESI†). The level of RPA/DNA complexes formed 
was inhibited by about 75%, 85% and 65% for H21, H45 and 
H69, respectively, in the presence of 2.5 mM of 360A. Raising the 
concentration  of  ligand  to  5  mM  resulted  only  in  a   slight 
 
 
Fig. 4 (A) Percentage of inhibition of RPA binding to telomeric oligo- 
nucleotide substrates H21 and H69 in the presence of increasing con- 
centrations of 360A (open circles) or (360A)2A (black squares) (B) 
percentage of displacement of RPA from the telomeric oligonucleotide 
substrates H21 and H69 (20 min incubation) upon addition of increasing 
amounts of 360A (open circles) or (360A)2A (black squares). 
 
 
   
 
 
increase in RPA binding inhibition by about 5% for all binding 
substrates. The dimer (360A)2A exhibited a greater inhibitory 
effect on RPA binding to the telomeric sequences, reaching 
about 95% inhibition for all binding substrates at 2.5 mM 
ligand concentration in solution (Fig. 4A). By contrast, we did 
not observe such inhibition of RPA binding to control    oligo- 
nucleotides that do not fold into G4s (Table S1 and Fig. S8, 
Notes and references 
§ The choice of a sodium buﬀer was privileged because of the less 
polymorphic nature of the telomeric G4 structure in this condition, similar 
results were obtained in a potassium-containing buﬀer (Fig. S2, ESI†). 
1 (a) R. K. Moyzis, J. M. Buckingham, L. S. Cram, M. Dani,  L.  L.  
Deaven, M. D. Jones, J. Meyne, R. L. Ratliﬀ and J. R. Wu, Proc. Natl. 
Acad.  Sci.  U.  S.  A.,  1988,  85,  6622–6626;  (b)  R.  McElligott and 
ESI†). These results suggested that more stable small mole- R. J. Wellinger, EMBO J., 1997, 16,  3705–3714. 2  ramanian, Nat. 
cule/DNA complexes are formed between the dimeric ligand 
and the higher-order G4 structures than with the monomeric 
ligand. This was further corroborated by UV-melting experi- 
ments that showed higher thermal stabilities of the complexes 
formed with (360A)2A as compared with 360A for an identical 
aromatic core to G4 unit ratio (Table S3, ESI†). 
In the nucleus of a cell, RPA may already be associated with 
telomeric DNA. We then asked whether our ligands were able to 
displace RPA from telomeric DNA. We hence performed experi- 
ments where the DNA binding substrates were pre-coated with 
RPA (20 min incubation) before the addition of the G4 ligand in 
the mixture for 5 min incubation. We observed that, under 
these experimental conditions, both G4 ligands were able to 
displace RPA from the DNA substrates in a concentration-  
dependent manner (Fig. 4B). We also performed control experi- 
ments, in the presence of a large excess of double-stranded  
competitor or with mutated telomeric oligonucleotide sub- 
strates, demonstrating the  G4  selectivity  of  the  ligands   
(Fig. S7  and S8,  ESI†). Importantly,  the dimer  (360A)2A dis- 
played a greater eﬃciency in displacing RPA from    telomeric 
DNA. When considering the longer sequence H69, 5 mM of 
(360A)2A dissociated about 60% of the RPA/DNA complex, while 
at the same concentration the 360A molecule dissociated only 
20% of the complex. It is noteworthy than even for the same 
concentration in G4-binding aromatic moiety (i.e. 2.5 mM in 
(360A)2A versus 5 mM in 360A), the dimer molecule was more 
eﬃcient in displacing RPA than the monomer (Fig. 4B). 
In conclusion, we undertook here to evaluate the binding 
properties of a known G4 ligand and its new dimeric analogue 
towards human telomeric higher-order G4 structures. Our 
results propose original binding modes for these ligands, 
which have never been reported before with other ligands. 
Furthermore,  we  showed  that  the   dimeric   ligand   is   
more eﬃcient than the monomer for  impairing  the  forma- 
tion and for inducing the dissociation of the complex formed 
RPA and human telomeric DNA, thus highlighting the 
potential of dimeric G4 ligands to eﬃciently interfere with 
protein binding at telomeres in order to interrogate telomere 
biology. 
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increasing amounts of 360A and (360A)2A. 
Fig. S5 Changes in the CD spectra and the maximum CD values of H45(TTA)3 and H69(TTA)3 in 10 
mM lithium cacodylate pH 7.2, 100 mM NaCl. 
Fig. S6 (A) Percentage of inhibition of RPA binding to telomeric oligonucleotide substrate H45 in the 
presence of increasing concentrations of 360A or (360A)2A for 5 min prior to incubation with RPA for 
20 min. (B) Percentage of displacement of RPA from the telomeric oligonucleotide substrate H45 
upon addition of increasing amounts of 360A or (360A)2A. 
Fig. S7 (A) Percentage of inhibition of RPA binding to telomeric oligonucleotide substrate H69 with 5 
µM of 360A or 2.5 µM of (360A)2A for 5 min in the presence of double-stranded competitor  ds26  
prior to incubation with RPA for 20 min. (B) Percentage of displacement of RPA from the telomeric 
oligonucleotide substrate H69 (20 min incubation) in the presence of double-stranded competitor ds26 
upon addition of 5 µM of 360A or 2.5 (360A)2A  µM for 5 min. 
Fig. S8 (A) Percentage of inhibition of RPA binding to mutated telomeric oligonucleotide substrates 
H27mut, H51mut and H75mut in the presence of increasing concentrations of 360A or (360A)2A for 5 
min prior to incubation with RPA for 20 min. (B) Percentage of displacement of RPA from the 
mutated telomeric oligonucleotide substrates H27mut, H51mut and H75mut upon addition of 
increasing amounts of 360A or (360A)2A. 
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Table S1: Sequences of the oligonucleotides used in this study 
Sequence 
name 
Number of 
G4 unit 
Sequence (5’ to 3’) 
H21 1 (GGGTTA)3GGG 
H45 2 (GGGTTA)7GGG 
H69 3 (GGGTTA)11GGG 
H93 4 (GGGTTA)15GGG 
H45(TTA)3 2 (GGGTTA)3GGG(TTA)3(GGGTTA)3GGG 
H69(TTA)3 3 [(GGGTTA)3GGG(TTA)3]2(GGGTTA)3GGG 
H27mut 0 TTAGGCTTACGGTTAGCGTTACGGTTA 
H51mut 0 TTAGGCTTACGGTTAGCGTTACGGTTAGGCTTACGGTT 
AGCGTTACGGTTA 
H75mut 0 TTAGGCTTACGGTTAGCGTTACGGTTAGGCTTACGGTT 
AGCGTTACGGTTAGGCTTACGGTTAGCGTTACGGTTA 
ds26 0 CAATCGGATCGAATTCGATCCGATTG 
 
 
Table S2: Calculated theoretical and obtained experimental values of the ligand to G4 unit 
molar ratios 
Oligonucleotide Number of 
G4 unit 
(nG4) 
Number 
of TTA 
linker 
(nTTA) 
360A (360A)2A 
Cal.a Exp. Cal.a Exp. 
H21 1 0 2.00 1.87 ± 0.13 1.00 1.22 ± 0.12 
H45 2 1 2.50 2.52 ± 0.18 1.50 1.55 ± 0.08 
H69 3 2 2.67 2.74 ± 0.08 1.67 1.63 ± 0.07 
H93 4 3 2.75 2.71 ± 0.11b 1.75 1.66 ± 0.06 b 
a Theoretical ligand/G4 unit molar ratio values were calculated as: 
(2*nG4+nTTA)/nG4, for 360A and (nG4+nTTA)/nG4, for (360A)2A 
b Experimental data for H93 are presented in Figure S4 
 
 
Table S3: Apparent UV-melting temperatures (TmAPP) of the complexes formed between the 
oligonucleotides and the G4 ligands 
Oligonucleotide 
(concentration) 
Tm (°C) TmAPP (°C)a TmAPP (°C)a 
DNA DNA + 360A (2eq. G4) DNA + (360A)2A ( 1eq. G4) 
H21 (3 µM) 60 64 70 
H45 (1.5 µM) 53 70 73 
H69 (1 µM) 47 70 74 
a Values are given with an experimental error of ± 1°C 
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Fig. S1 (A) FRET melting curves of F21T (black) in the presence of (a) 1 µM of 360A, (b) 
0.5 µM and (c) 1 µM of (360A)2A, without (red) or with 3 µM (blue) or 10 µM (green) of 
double-stranded competitor ds26. (B) Representative FRET melting curves of H69Q1 (black) 
in the presence of 1.5 µM of (360A)2A without (red) or with (blue) 10 µM of double-stranded 
competitor ds26. (C) FRET melting temperatures of H69Q1, H69Q2 and H69Q3 in the 
absence (grey bars) and in presence of 1.5 µM of (360A)2A  without (black bars) or with 10 
µM (white bars) of ds26. Errors bars are standard deviation on triplicate. 
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Fig. S2 (A,C and E) Changes in the CD spectra and (B, D and F) changes in the maximum  
CD values of H21 (6 μM), H45 (3 μM) and H69 (2 μM) upon addition of increasing amounts 
of (360A)2A in 10 mM lithium cacodylate pH 7.2, 10 mM KCl, 90 mM LiCl. The CD spectra 
in the absence of the ligand are in red. 
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Fig. S3 (A and C) Changes in the CD spectrum and (B and D) changes in the maximum CD 
value of H45 (3 µM in 10 mM lithium cacodylate pH 7.2, 100 mM NaCl) upon addition of 
increasing amounts of 360A and (360A)2A. The CD spectrum without ligand is in red. 
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Fig. S4 (A and C) Changes in the CD spectrum and (B and D) changes in the maximum CD 
value of H93 (1.5 µM in 10 mM lithium cacodylate pH 7.2, 100 mM NaCl) upon addition of 
increasing amounts of 360A and (360A)2A. The CD spectrum without ligand is in red. 
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Fig. S5 Changes in the CD spectra and in the maximum CD values of (A-D) H45(TTA)3 (3 
μM) and (E-H) H69(TTA)3 (2 μM) upon addition of increasing amounts of 360A and 
(360A)2A in 10 mM lithium cacodylate pH 7.2, 100 mM NaCl. The CD spectra in the absence 
of the ligands are in red. 
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Fig. S6 (A) Percentage of inhibition of RPA binding to telomeric oligonucleotide substrate 
H45 in the presence of increasing concentrations of 360A (open circles) or (360A)2A (black 
squares) for 5 min prior to incubation with RPA for 20 min. (B) Percentage of displacement  
of RPA from the telomeric oligonucleotide substrate H45 (20 min incubation) upon addition 
of increasing amounts of 360A (open circles) or (360A)2A (black squares) for 5 min. 
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Fig. S7 (A) Percentage of inhibition of RPA binding to telomeric oligonucleotide substrate 
H69 with 5 µM of 360A (grey bars) or 2.5 µM of (360A)2A (black bars) for 5 min in the 
presence of double-stranded competitor ds26 prior to incubation with RPA for 20 min. (B) 
Percentage of displacement of RPA from the telomeric oligonucleotide substrate H69 (20 min 
incubation) in the presence of double-stranded competitor ds26 upon addition of 5 µM of 
360A (grey bars) or 2.5 (360A)2A µM (black bars) for 5 min. 
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Fig. S8 (A) Percentage of inhibition of RPA binding to mutated telomeric oligonucleotide 
substrates H27mut, H51mut and H75mut in the presence of increasing concentrations of  
360A (grey bars) or (360A)2A  (black bars) for 5 min prior to incubation with RPA for 20 min. 
(B) Percentage of displacement of RPA from the mutated telomeric oligonucleotide substrates 
H27mut, H51mut and H75mut (20 min incubation) upon addition of increasing amounts of 
360A (grey bars) or (360A)2A (black bars) for 5 min. 
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Materials and methods 
Oligonucleotides 
Reverse-phase HPLC-purified oligonucleotides were purchased from Eurogentec 
(Belgium). They were dissolved in bi-distilled water and stored at -20°C. Concentrations were 
determined by UV absorption in bi-distilled water, using the molar extinction coefficients 
provided by the manufacturer. 
 
Biochemical reagents 
BSA was purchased from Roche, γ32P-ATP was from PerkinElmer Life Sciences and 
T4 polynucleotide kinase was from New England Biolabs. 
Recombinant hRPA was expressed in the E. coli BL21 (DE3) strain transformed with plasmid 
pET11a-hRPA that affords co-expression of RPA1, RPA2 and RPA3 subunits. The protein 
complex was purified as previously described.S1 
 
Chemical reagents and instrumentations 
Chemical reagents were purchased from Sigma-Aldrich and Fluka. Solvents were 
obtained from Carlo Erba. They were used without additional purification. Microwave  
heating was performed in a microwave synthesis reactor Monowave 300 (Anton Paar). 
Reverse-phase HPLC analysis and purification were performed on Agilent Technologies 1200 
analytical and preparative apparatus piloted by an Agilent ChemStation program. In analytical 
HPLC standard conditions, compounds were analysed using a 25 min linear gradient of 0-to- 
100% water-acetonitrile-0.1% TFA on an analytical (4.6 x 250 mm) Kinetecs C18 EVO 5 μm 
column (Phenomenex) at the flow rate of 1 mL.mn-1, with detection by UV-absorption at both 
260 and 310 nm. Reverse-phase preparative HPLC purifications were performed on a Waters 
column (Xbridge C18 5 µm, 19 × 250 mm) using a 25 min linear gradient of 0-100% water- 
acetonitrile, containing 0.1% TFA, and monitored by UV detection at both 260 and 310 nm. 
Mass spectrometry analysis by ESI Q-TOF was performed on a Q-Star instrument (Applied 
Biosystems) in the positive mode; analyses were performed in methanol or DMF. NMR 
spectra were recorded on a Bruker AVANCE 400 NMR spectrometer equipped with a 1-H 
broad-band reverse gradient probehead. Stock solutions of the ligands (5 mM) were prepared 
in DMSO and stored at -20°C. 
 
Chemical synthesis 
Synthesis of 360A molecule was carried out as previously described.S2 
The dimer ligand (360A)2A was prepared with a 32% overall yield following the three-step 
process depicted below. 
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a) 4-aminobutyric acid / TEA / 2.5 h microwave heating in DMF at 140°.  b) hexane-1,6-diamine / EDCI / HOBt / 4 days at    room temperature in DMF. 
c) excess methyl iodide / 4 h microwave heating in DMF at 110°. 
4-[2,6-bis(quinolin-3-yl)aminocarbonyl-pyridin-4-yl)aminobutyric acid (1): 
To a solution of 136 mg (0.3 mmol) of N2,N6-(quinolin-3-yl)-4-chloro-pyridine-2,6- 
dicarboxamide in DMF (5 mL) were added 34 mg (0.33 mmol) of 4-aminobutyric acid and 42 
µL (0.3 mmol) of triethylamine. After 2.5 h heating at 140°C in a microwave reactor and 
dilution with water (5 mL), the resulting colloidal mixture was centrifuged for 15 min at 4000 
rpm. The solid was washed by centrifugation with 50% aqueous DMF (2 mL) and twice with 
water (10 mL), then dried 50°C under vacuum, yielding 72 mg (46%) of almost pure (1), as  
an off-white powder (m.p. > 260°C). 
Rt (in standard analytical HPLC conditions) = 16.8 min. 
1H NMR (400MHz, DMSO) δ (ppm) = 12.3-12.5 (1H, bs), 11.4 (2H, s), 9.4 (2H, s), 8.95  
(2H, s), 8.05 (4H, m), 7.8 (2H, s), 7.65 (2H, m), 7.55 (2, m), 5.6 (m, 1H), 4.35 (m, 2H), 2.4 
(m, 2H), 1.65 (m, 2H). 
SM (ESI-Q-TOF): [M+H] + = 521.45. 
 
1,6-{4-[2,6-bis(quinolin-3-yl)aminocarbonyl-pyridin-4-yl]amino-butanoyl}hexane-1,6- 
diamine (2) : 
62.5 mg (120 µmol) of (1) and 15 mg (65 µmol) of hexane-1,6-diamine were dissolved in dry 
DMF (2 mL). 23 mg (120 µmol) of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) 
and 3.4 mg (25 µmol) of 1-hydroxybenzotriazole (HOBt) were then added. After 4 days 
stirring at room temperature the yellow solution was diluted with water (2 mL). The white 
colloidal precipitate formed was separated by centrifugation at 4000 pm for 15 min, washed 
with water and dried at 50°C under vacuum. The crude product, dissolved in DMF, was 
purified by reverse-phase preparative HPLC in the conditions previously described and 
yielded 57 mg (85%) of (2) as a white solid (m.p. > 260°C). 
Rt (in standard analytical HPLC conditions) = 19.5 min. 
SM (ESI-Q-TOF): [M+H] + = 1121.21. 
 
1,6-{4-[2,6-bis(1-methyl-quinolinio-3-yl)aminocarbonyl-pyridin-4-yl]amino- 
butanoyl}hexane-1,6-diamine, tetra iodide ((360A)2A ): 
N N 
– 
b c 
N N 
N N 
O 
N 
N H H N 
N + 
I – I – 
N + 
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56 mg (50 µmol) of (2) and 250 µL (567 mg, 4 mmol) of methyl iodide were dissolved in 
DMF (1.5 mL) and heated at 110°C for 4 h in a microwave reactor. By cooling at room 
temperature, crystals separated that were filtered-off, washed successively with DMF (2 x 0.2 
mL), ethanol (2 x 0.5 mL) and diethyl ether (2 x 2 mL) and dried, yielding 67 mg (79%) of 
pure (360A)2A, as bright yellow crystals. 
Rt (in standard analytical HPLC conditions) = 18.7 min. 
SM (ESI-Q-TOF): [M+2H] 2+ = 589.60; [M+H] + = 1179.21. 
 
 
Spectroscopic measurements 
Oligonucleotide samples were prepared in a 10 mM cacodylic acid buffer at pH 7.2 in 
bi-distilled water (adjusted with LiOH), containing 100 mM NaCl or 10 mM KCl plus 90 mM 
LiCl, and placed in quartz cells (Hellma) with an optical pathway of 1 cm. 
CD spectra were recorded on a J-810 spectropolarimeter (Jasco) at 20°C, after 
annealing of the oligonucleotide samples by heating at 95°C on a heat block, followed by a 
slow cool down to room temperature. Measurements were carried out in quartz cells (Hellma) 
with an optical pathway of 1 cm. CD spectra were obtained by averaging three scans at a 
scanning rate of 500 nm.min-1. They were baseline corrected by subtracting the spectrum of a 
water filled quartz cell and zero corrected at 340 nm. Titration experiments were performed 
by incremental additions of 3 µL of a 180 µM ligand solution, prepared in a 1X ad hoc buffer 
from a 5 mM stock solution in DMSO, in a 540 µL oligonucleotide solution. CD signal 
amplitudes were corrected for the dilution factor resulting from ligand additions. 
UV-melting profiles were recorded on an Uvikon XL spectrophotometer (Secomam) 
equipped with a circulating water bath (Julabo) and a dry airflow in the sample compartment. 
Samples were heated at 95°C for 2 min, cooled down at 5°C, and then heated back at 95°C, at 
a rate of 0.2°C.min-1. UV absorbance was recorded at 245, 260, 273, 295 and 335 nm every 5 
min. Temperature was measured with a glass sensor immersed into a water filled quartz cell. 
Melting temperature (Tm) was obtained as the maximum of the first derivative of the melting 
profile recorded at 273 nm. 
 
FRET melting experiment 
FRET melting experiments were performed in 96-well plates with F21T (FAM- 
G3[T2AG3]3-Tamra, with FAM: 6-carboxyfluorescein and Tamra: 6- 
carboxytretramethylrhodamine) and three modified H69 oligonucleotides, doubly labelled 
with FAM and a TAMRA at different : in H69Q1, the fluorophores are placed at both sides of 
the first (5’) G4 unit, in H69Q2, they are placed at both sides of the second G4 unit and in 
H69Q3, they are placed at both sides of the third (3’) G4 unit. Fluorescence melting curves 
were recorded with a Mx300P real-time PCR instrument (Stratagene), using a total reaction 
volume of 25 µL, with 0.2 µM of oligonucleotide in a 10 mM cacodylic acid buffer at pH 7.2 
in bi-distilled water (adjusted with LiOH) containing 100 mM NaCl. After a first equilibration 
step at 25°C during 5 min, a stepwise increase of 1°C for 70 cycles to reach 95°C was 
performed and measurements were made done after each cycle with excitation at 492 nm and 
detection at 516 nm. The melting of the G-quadruplex was monitored alone or with the  
ligands 360A or (360)2A, and in the absence or in the presence of double-stranded competitor 
ds26 (Table S1). 
 
RPA binding assays 
Oligonucleotides were labelled with γ32P-ATP using T4 polynucleotide kinase. They 
were separated from non-incorporated γ32P-ATP through Biospin 6 columns (Biorad) 
according to the manufacturer’s protocol. Prior binding experiments, stock solutions of hRPA 
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were diluted and pre-incubated 10 min at 4°C in a buffer containing 50 mM Tris-HCl, pH 7.5, 
100 mM KCl, 1 mM DTT, 10% glycerol, 0.2 mg/mL BSA and 0.1 mM EDTA. 
Binding experiments were carried out in 10 µl samples prepared in a reaction buffer 
containing 50 mM HEPES, pH 7.9, 0.1 mg/mL BSA, and 100 mM NaCl and 2% glycerol. For 
the first set of experiments, radiolabeled oligonucleotides (2 nM) were first incubated for 5 
min at room temperature (∼ 20°C) with various amounts of G4 ligands (0, 1.25, 2.5 or 5 µM 
final concentrations) before addition of RPA (100-200 nM final concentration), and further 
incubation for 20 min at room temperature. In the displacement conditions, radiolabeled 
oligonucleotide substrates were first incubated with RPA for 20 min at room temperature 
prior to addition of the G4 ligands, and further incubation for 5 min. For experiments in the 
presence of double-stranded competitor ds26 (Table S1), the competitor was added at the 
same time as the radiolabeled oligonucleotide substrate. 
Samples were then loaded on native 1% agarose gels prepared with 0.5X TBE buffer. 
Electrophoresis was performed in 0.5X TBE running buffer for 90 min at 5 V/cm at room 
temperature in. Gel was then dried and exposed to a storage phosphor screen that was scanned 
with Typhoon™ FLA 95000 biomolecular imager (GE Healthcare). Band intensities (I) were 
quantified using ImageQuant 5.2. For each G4 ligand concentration, the fraction (F) of 
radiolabeled oligonucleotide substrate bound to RPA was calculated as Ioligo bound / (Ioligo bound + 
Ioligo free) and the RPA binding inhibition or displacement as (F0-Fc)/Fc, where F0 is the 
fraction of oligonucleotide bound in the absence of the ligand and Fc the fraction bound in the 
presence of the ligand at the indicated concentration. Experiments were performed at least 
twice, with error bars representing the standard error on the mean. 
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